Compare TYGO & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TYGO | NGNE |
|---|---|---|
| Founded | 2007 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 380.1M | 327.8M |
| IPO Year | 2021 | 2014 |
| Metric | TYGO | NGNE |
|---|---|---|
| Price | $4.80 | $26.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $6.00 | ★ $63.57 |
| AVG Volume (30 Days) | ★ 537.1K | 151.1K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 97.12 | 0.93 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $103,536,000.00 | N/A |
| Revenue This Year | $30.78 | N/A |
| Revenue Next Year | $21.68 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 91.68 | N/A |
| 52 Week Low | $0.81 | $11.78 |
| 52 Week High | $5.33 | $37.27 |
| Indicator | TYGO | NGNE |
|---|---|---|
| Relative Strength Index (RSI) | 59.79 | 61.81 |
| Support Level | $3.24 | $19.40 |
| Resistance Level | N/A | $29.05 |
| Average True Range (ATR) | 0.46 | 1.99 |
| MACD | 0.05 | 0.05 |
| Stochastic Oscillator | 68.85 | 78.42 |
Tigo Energy Inc provides solar and energy storage solutions, including module level power electronics (MLPE) designed to maximize the energy output of individual solar modules, delivering more energy, active management, and enhanced safety for utility, commercial, and residential solar arrays. By combining its MLPE and solar optimizer technology with intelligent, cloud-based software capabilities, the Company enables developed energy monitoring, system diagnostics, and real-time control. Geographically the company generates revenue from EMEA, Americas, and APAC.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.